See more : CSBC Corporation (2208.TW) Income Statement Analysis – Financial Results
Complete financial analysis of NeuroSense Therapeutics Ltd. (NRSN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeuroSense Therapeutics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Saudi Pharmaceutical Industries and Medical Appliances Corporation (2070.SR) Income Statement Analysis – Financial Results
- Goldtek Technology Co., Ltd. (6638.TWO) Income Statement Analysis – Financial Results
- Xtep International Holdings Limited (1368.HK) Income Statement Analysis – Financial Results
- Pasithea Therapeutics Corp. (KTTAW) Income Statement Analysis – Financial Results
- Xalles Holdings Inc. (XALL) Income Statement Analysis – Financial Results
NeuroSense Therapeutics Ltd. (NRSN)
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 97.00K | 89.00K | 3.00K | 3.00K | 0.00 |
| Gross Profit | -97.00K | -89.00K | -3.00K | -3.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.27M | 6.42M | 3.08M | 2.50M | 898.00K |
| General & Administrative | 4.78M | 7.14M | 2.51M | 393.00K | 337.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.78M | 7.14M | 2.51M | 393.00K | 337.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.29M | 13.55M | 5.59M | 2.89M | 1.24M |
| Cost & Expenses | 10.29M | 13.55M | 5.59M | 2.89M | 1.24M |
| Interest Income | 178.00K | 91.00K | 0.00 | 61.00K | 18.00K |
| Interest Expense | 550.00K | 15.00K | 1.15M | 1.00K | 5.00K |
| Depreciation & Amortization | 97.00K | 89.00K | 3.00K | 3.00K | 1.24M |
| EBITDA | -10.63M | -13.38M | -2.88M | -2.83M | -1.25M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -12.05M | -13.55M | -5.59M | -2.89M | -1.24M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 769.00K | 1.21M | 1.55M | 60.00K | 13.00K |
| Income Before Tax | -11.28M | -12.34M | -4.04M | -2.83M | -1.22M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.14M | -1.55M | 1.00K | 5.00K |
| Net Income | -10.11M | -11.20M | -2.50M | -2.83M | -1.23M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.83 | -0.97 | -1.29 | -1.46 | -0.63 |
| EPS Diluted | -0.83 | -0.97 | -1.29 | -1.46 | -0.63 |
| Weighted Avg Shares Out | 13.64M | 11.50M | 1.94M | 1.94M | 1.94M |
| Weighted Avg Shares Out (Dil) | 13.64M | 11.50M | 1.94M | 1.94M | 1.94M |
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS
In participants who received PrimeC from the start of the 18-month study compared to those initially on placebo before transitioning to PrimeC, disease progression was slowed by 33% (p=0.007), demonstrated in a 58% improvement in survival rates Consistent data across subgroups...
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
CAMBRIDGE, Mass. , Dec. 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND
CAMBRIDGE, Mass. , Nov. 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
Meeting discussion to focus on finalizing Phase 3 study design and NDA readiness, ensuring a clear regulatory path for submission based on trial success Parallel preparations in Canada: NeuroSense plans to submit its dossier in Q2 2025, with a regulatory decision on...
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients
Groundbreaking PARADIGM Trial Offers New Hope for ALS Treatment CAMBRIDGE, Mass. , Oct. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
Dossier submission planned for Q2 2025; regulatory decision expected by Q1 2026 Estimated potential market opportunity: peak of $100M to $150M in annual revenue Company aims to expand approval efforts to additional global markets CAMBRIDGE, Mass. , Oct. 15, 2024...
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
The preparations for the regulatory submission for early commercialization in Canada follows the positive Phase 2b trial results which show PrimeC reduces ALS disease progression by 36% and improves survival rates by 43% Company plans to seek approval in additional...
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting
CAMBRIDGE, Mass. , Oct. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's
The Company's intellectual property now covers the combination, formulation, and method of use of PrimeC Patent protection extends through 2042, adding four additional years to PrimeC's IP umbrella CAMBRIDGE, Mass. , Sept. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
CAMBRIDGE, Mass. , Sept. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Source: https://incomestatements.info
Category: Stock Reports